Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:77999
Structure:
Synonyms:
122320-73-4
2,4-Thiazolidinedione,
2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-
2,4-Thiazolidinedione, 5-004-02-((((methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-
2,4-thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-
2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI)
5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
5-((4-(2-Methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate
5-(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione
5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
5-[[4-[2-(methyl-(2-pyridyl)amino)ethoxy]phenyl]methyl] thiazolidine-2,4-dione
5-[[4-[2-(methyl-pyridin-2-ylamino)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
Avandaryl
Avandia
BB_SC-4138
Brl 49653
Brl-49653
BRL49653
BSPBio_002693
C18H19N3O3S
CHEBI:50122
DB00412
IDMB (1uM BRL49653, 1uM Dexamethasone, 0.5uM IBMX, 10ug/mL Insulin)
KBio2_002183
KBio2_004751
KBio2_007319
KBio3_001913
KBioGR_001609
KBioSS_002183
LS-151340
NCGC00095124-01
NCGC00095124-02
NCGC00095124-03
RGZ
Rosi
Rosigilitazone
Rosigliazone maleate
Rosiglitazone
rosiglitazone (Avandia)
Rosiglitazone maleate
Rosiglitazone [INN:BAN]
Rosiglizole
RSG
S00306
SPBio_001142
SPECTRUM1504263
Spectrum2_001241
Spectrum3_000997
Spectrum4_001125
Spectrum5_001464
Spectrum_001703
TDZ 01
[3H]rosiglitazone
ATC-Codes:
Side-Effects:
Side-EffectFrequency
abdominal pain0.0010
hyperbilirubinemia0.0010
hyperglycemia0.0010
hypoglycemia0.0010
influenza0.0010
nasopharyngitis0.0010
nausea0.0010
pain0.0010
pleural effusions0.0010
pruritus0.0010
pulmonary edema0.0010
sinusitis0.0010
stevens - johnson syndrome0.0010
upper respiratory tract infection0.0010
urticaria0.0010
vomiting0.0010
hepatic failure0.0010
hepatitis0.0010
congestive heart failure0.0010
cardiac failure0.0010
anaphylactic reaction0.0010
anemia0.0010
angioedema0.0010
back pain0.0010
cough0.0010
type 2 diabetes0.0010
diabetic ketoacidosis0.0010
diarrhea0.0010
dizziness0.0010
dysmenorrhea0.0010
headache0.0010
edema0.0010
rash0.0010
weight gain0
fatigue0
hypertension0
arthralgia0
constipation0
myocardial infarction0
myocardial ischemia0

Target

show target details
Uniprot ID:Q62710_RAT
Synonyms:
Nitric oxide synthase
EC-Numbers:-
Organism:Rat
Rattus norvegicus
PDB IDs:-

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

14709329
Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation.. Salvatore Cuzzocrea; Barbara Pisano; Laura Dugo; Angela Ianaro; Pasquale Maffia; Nimesh S A Patel; Rosanna Di Paola; Armando Ialenti; Tiziana Genovese; Prabal K Chatterjee; Massimo Di Rosa; Achille P Caputi; Christoph Thiemermann (2004) European journal of pharmacology display abstract
Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily of ligand-activated transcription factors that are related to retinoid, steroid and thyroid hormone receptors. The PPAR-gamma receptor subtype appears to play a pivotal role in the regulation of cellular proliferation and inflammation. The thiazolidinedione rosiglitazone (Avandia) is a peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist, that was recently approved by the Food and Drug Administration for treatment of type II diabetes mellitus. In the present study, we have investigated the effects of rosiglitazone in animal models of acute inflammation (carrageenan-induced paw oedema and carrageenan-induced pleurisy). We report here for the first time that rosiglitazone (given at 1, 3 or 10 mg/kg i.p. concomitantly with carrageenan injection in the paw oedema model, or at 3, 10 or 30 mg/kg i.p. 15 min before carrageenan administration in the pleurisy model) exerts potent anti-inflammatory effects (e.g. inhibition of paw oedema, pleural exudate formation, mononuclear cell infiltration and histological injury) in vivo. Furthermore, rosiglitazone reduced: (1) the increase in the staining (immunohistochemistry) for nitrotyrosine and poly (ADP-ribose) polymerase (PARP), (2) the expression of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), intercellular adhesion molecules-1 (ICAM-1) and P-selectin in the lungs of carrageenan-treated rats. In order to elucidate whether the protective effect of rosiglitazone is related to activation of the PPAR-gamma receptor, we also investigated the effect of a PPAR-gamma antagonist, bisphenol A diglycidyl ether (BADGE), on the protective effects of rosiglitazone. BADGE (30 mg/kg i.p.) administered 30 min prior to treatment with rosiglitazone significantly antagonized the effect of the PPAR-gamma agonist and thus abolished the anti-inflammatory effects of rosiglitazone. We propose that rosiglitazone and other potent PPAR-gamma agonists may be useful in the therapy of inflammation.